No profile data available.
ImmuPharma plc (IMM.L) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in London, United Kingdom, with about 7 full-time employees.
It reported revenue of 0 GBP for fiscal year 2024, and net income of -2.48 million GBP. Its market capitalization was 25.01 million GBP as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally.
ImmuPharma reported 0 GBP in revenue for fiscal year 2024.
25.01 million GBP as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Sareum Holdings plc (SAR.L).